Preclinical Models of Alzheimer's Disease: Relevance and Translational Validity

Current Protocols in Pharmacology
Kevin Mullane, Michael Williams

Abstract

The only drugs currently approved for the treatment of Alzheimer's Disease (AD) are four acetylcholinesterase inhibitors and the NMDA antagonist memantine. Apart from these drugs, which have minimal to no clinical benefit, the 40-year search for effective therapeutics to treat AD has resulted in a clinical failure rate of 100% not only for compounds that prevent brain amyloid deposition or remove existing amyloid plaques but also those acting by a variety of other putative disease-associated mechanisms. This indicates that the preclinical data generated from current AD targets to support the selection, optimization, and translation of new chemical entities (NCEs) and biologics to clinical trials is seriously compromised. While many of these failures reflect flawed hypotheses or a lack of adequate characterization of the preclinical pharmacodynamic and pharmacokinetic (PD/PK) properties of lead NCEs-including their bioavailability and toxicity-the conceptualization, validation, and interrogation of the current animal models of AD represent key limitations. The overwhelming majority of these AD models are transgenic, based on aspects of the amyloid hypothesis and the genetics of the familial form of the disease. As a result, thes...Continue Reading

References

Sep 1, 1976·European Journal of Intensive Care Medicine·I Hessov, M Bojsen-Møller
Feb 1, 1979·Journal of Comparative and Physiological Psychology·C A Barnes
Apr 1, 1976·Archives of Neurology·H LijtmaerR Katzman
Apr 10, 1992·Science·J A Hardy, G A Higgins
Apr 1, 1989·Trends in Neurosciences·T I Bonner
Nov 1, 1988·Behavioural Brain Research·A Ennaceur, J Delacour
Jul 30, 1982·Science·R T BartusA S Lippa
Jun 24, 1982·Nature·R G MorrisJ O'Keefe
May 1, 1994·Brain Research. Brain Research Reviews·A H Gouliaev, A Senning
Nov 30, 1993·Behavioural Brain Research·G L Wenk
Sep 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·W WallaceV Haroutunian
Jan 1, 1997·Experimental Gerontology·T TakedaK Higuchi
Dec 16, 1997·Proceedings of the National Academy of Sciences of the United States of America·C Sturchler-PierratB Sommer
Nov 21, 1998·European Journal of Clinical Investigation·U Ebert, W Kirch
Mar 20, 2002·Pharmacology, Biochemistry, and Behavior·Nuria Estapé, Thomas Steckler
Jan 25, 2003·Experimental Gerontology·C A Erickson, C A Barnes
Jul 16, 2003·Journal of Neurochemistry·Cathy AndorferPeter Davies
Jun 24, 2004·Neurobiology of Aging·Joanna L JankowskyDavid R Borchelt
Aug 28, 2004·The Milbank Quarterly·Maxwell J Mehlman
Nov 18, 2005·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Martin RamsdenKaren H Ashe
Apr 5, 2007·Nature Protocols·Charles V Vorhees, Michael T Williams
Jul 31, 2007·Biochemical Pharmacology·Stephen P ArnericMichael Williams
Feb 15, 2008·Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases·Sean ScottJames A Heywood

❮ Previous
Next ❯

Citations

Apr 20, 2019·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Solomon Habtemariam
Sep 19, 2019·Current Protocols in Neuroscience·Ariana Myers, Paul McGonigle
Jan 3, 2020·The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences·Christy S CarterSteven Austad
Jun 23, 2020·Protein Science : a Publication of the Protein Society·Jacques FantiniNouara Yahi
Sep 26, 2020·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Xu-Qiao ChenWilliam C Mobley
Dec 24, 2019·Frontiers in Aging Neuroscience·Ashok N HegdeSavannah Vaz
Jul 3, 2020·Nature Reviews. Drug Discovery·Kimberly Scearce-LevieJoseph W Lewcock
Oct 24, 2019·Journal of Alzheimer's Disease : JAD·Maria Lo GiudiceJulianna Kobolák
Jul 24, 2020·Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research·Allison Bethanne ReissMark M Stecker
Aug 6, 2019·Frontiers in Pharmacology·Dalila MangoRobert Nisticò
Jul 11, 2019·European Journal of Pharmacology·Désirée H Veening-GriffioenHuub Schellekens
Jul 22, 2019·Trends in Pharmacological Sciences·Manish D ParanjpeMarina Sirota
Jan 13, 2021·ELife·Natascha Ingrid DrudeUlf Toelch
Nov 17, 2020·Biomaterials Science·Daniela Peneda PachecoPaola Petrini
Feb 10, 2021·Neuropharmacology·Marc R PlagenhoefAlvin V Terry
Jan 20, 2020·Neuroscience Research·Yuichi Takeuchi, Antal Berényi
May 1, 2021·International Journal of Molecular Sciences·Katrina AlbertŠárka Lehtonen
Apr 16, 2021·Current Alzheimer Research·Li GuoM Francesca Cordeiro
Nov 16, 2021·Current Protocols·Michael Williams

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a neurodegenerative disease. This feed focuses on the underlying role of tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's disease.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.